TNB-738 is under clinical development by Ancora Biotech and currently in Phase I for Unspecified Immunological Disorders.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Insulin lispro U100 is under clinical development by Adocia and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

CP-506 is under clinical development by Convert Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

KITE-363 is under clinical development by Gilead Sciences and currently in Phase I for Unspecified B-Cell Lymphomas.

Plasmodium Immunotherapy is under clinical development by CAS-Lamvac Biotech and currently in Phase II for Colorectal Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Rectal Cancer. According to GlobalData, Phase I drugs for Rectal Cancer does not have sufficient historical ...

Paclitaxel is under clinical development by DAE HWA Pharmaceutical and currently in Phase I for Kaposi Sarcoma.

Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Small-Cell Lung Cancer.